STAT+: Pharmalittle: We’re reading about TrumpRx, Hims & Hers selling compounded Wegovy pill, and moreSTAT+: Pharmalittle: We’re reading about TrumpRx, Hims & Hers selling compounded Wegovy pill, and more
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda, so far, appears rather modest, given the frigid conditions awaiting us. We expect to catch up on our reading, check in on one Read More
STAT+: IPOs, GLP-1s, and challenges with a gene therapySTAT+: IPOs, GLP-1s, and challenges with a gene therapy
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We’ve made it to the end of what’s felt like an extremely long week. Wishing you all a restful weekend and lots of Super Bowl dips. Roivant’s immune drug helped treat rare Read More
Why some breast cancers evade treatment: Protein secreted by T cells may explain resistant tumorsWhy some breast cancers evade treatment: Protein secreted by T cells may explain resistant tumors
Up to 20% of hormone receptor-positive breast cancers don’t respond to antiestrogen therapies. A study led by researchers at UT Southwestern, published in the Journal of Clinical Investigation, suggests that a protein secreted by immune cells within these tumors causes them to grow even in the absence of estrogen.
Challenges for a crucial sickle cell treatment and the latest outlook for GLP-1sChallenges for a crucial sickle cell treatment and the latest outlook for GLP-1s
On this week’s episode of The Readout LOUD: two starkly different financial outlooks from Novo Nordisk and Eli Lilly, a psychedelics drug from Compass Pathways encountered a roadblock with the Trump White House, and a closer look at why manufacturing problems have slowed the rollout of a crucial sickle cell treatment. It’s our pre-Super Bowl show, Read More
STAT+: Novo Nordisk accuses Hims & Hers of ‘illegal mass compounding’ over a cheaper version of Wegovy pillSTAT+: Novo Nordisk accuses Hims & Hers of ‘illegal mass compounding’ over a cheaper version of Wegovy pill
In an unexpected move, Hims & Hers is making available a cheaper, compounded version of the Wegovy weight loss pill sold by Novo Nordisk, prompting the drugmaker to accuse the telehealth platform of “illegal mass compounding.” In announcing its move, Hims & Hers said it would make compounded copies of Wegovy available on its platform Read More
Hims & Hers Launches Copy of Wegovy Pill, Prompting Legal ThreatsHims & Hers Launches Copy of Wegovy Pill, Prompting Legal Threats
(MedPage Today) — Telehealth company Hims & Hers said Thursday it will launch a cheaper, off-brand version of the weight-loss pill semaglutide (Wegovy), just weeks after drugmaker Novo Nordisk launched its highly anticipated reformulation… (MedPage Today) — Telehealth company Hims & Hers said Thursday it will launch a cheaper, off-brand version of the weight-loss Read More
Novo Nordisk vows legal action to protect Wegovy pillNovo Nordisk vows legal action to protect Wegovy pill
Novo Nordisk said Thursday it would take legal action against a US chain offering a copycat of the new pill version of its Wegovy weight-loss drug. Novo Nordisk said Thursday it would take legal action against a US chain offering a copycat of the new pill version of its Wegovy weight-loss drug.
A sneak peek of pharma’s Super Bowl ads: GLP-1s, tight ends, and moreA sneak peek of pharma’s Super Bowl ads: GLP-1s, tight ends, and more
If there’s any event that draws a lot of attention to TV ads, it’s the Super Bowl. Drug companies usually sit on the sidelines for the annual advertising bonanza, and one might expect this Sunday’s game to be no different, considering the FDA’s recent crackdown on pharma ads. But that’s not the case. Novartis and Read More
Self-Acupressure for Fatigue in Patients Surviving Ovarian CancerSelf-Acupressure for Fatigue in Patients Surviving Ovarian Cancer
This randomized clinical trial investigates whether true self-acupressure, learned through a mobile app, improves cancer-related fatigue in women surviving ovarian cancer compared with sham self-acupressure and usual care.
A reliable atlas of cell types found in breast cancersA reliable atlas of cell types found in breast cancers
Breast cancer (BC) is the most common cancer and the second leading cause of cancer death in women. It is a highly variable disease, defined as a malignancy of the epithelial ducts in breast tissue. Characterizing the vast heterogeneity within BC cells and their surrounding tumor microenvironment is crucial because this diversity is the primary reason for treatment resistance, disease progression and poor patient prognosis.